TIDMAPH

RNS Number : 9489I

Alliance Pharma PLC

22 June 2017

 
 For immediate release   22 June 2017 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:

(a) Identity of the significant shareholder: GVQ Investment Management Limited

(b) Date of disclosure: 22 June 2017

   (c)   Date of relevant change: 21 June 2017 

(d) Price, amount and class: 1,000,000 ordinary shares of 1p each; price not disclosed

(e) Nature of transaction: sale of shares

   (f)   Nature and extent of significant shareholder's interest: direct and indirect interests 

(g) Resultant shareholding: 23,950,000 shares, with a direct interest in the shares and an indirect interest in the voting rights, in each case amounting to 5.05%

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

 
 Alliance Pharma plc                             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
  Andrew Franklin, Chief Financial 
  Officer 
 Rob Bellhouse, Company Secretary 
 www.alliancepharma.co.uk 
                                                     + 44 (0) 20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Cowles 
 
                                                     + 44 (0) 20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James 
  Black / Toby Adcock 
 

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 
-------------------------------------------------------------------------------------- 
 
 1. Identity of the issuer or                                          Alliance Pharma 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: 
----------------------------------------------------------  -------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
-------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                             X 
----------------------------------------------------------  -------------------------- 
 An acquisition or disposal of qualifying financial 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
----------------------------------------------------------  -------------------------- 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
----------------------------------------------------------  -------------------------- 
 An event changing the breakdown of voting rights 
----------------------------------------------------------  -------------------------- 
 Other (please specify): 
----------------------------------------------------------  -------------------------- 
 3. Full name of person(s)                                   GVQ Investment Management 
  subject to the                                              Ltd 
  notification obligation: 
----------------------------------------------------------  -------------------------- 
 4. Full name of shareholder(s)                              Nortrust Nominees Ltd 
  (if different from 3.): 
----------------------------------------------------------  -------------------------- 
 5. Date of the transaction                                  21/06/2017 
  and date on 
  which the threshold is 
  crossed or 
  reached: 
----------------------------------------------------------  -------------------------- 
 6. Date on which issuer                                     22/06/2017 
  notified: 
----------------------------------------------------------  -------------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached:                                                   5% 
----------------------------------------------------------  -------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares 
---------------------------------------------------------------------------------------------------------------------- 
 Class/type     Situation previous                  Resulting situation after the 
  of             to the triggering                   triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  ----------------------------------  ------------------------------------------------------------------- 
                Number            Number            Number          Number of                 % of voting 
                 of                of                of shares       voting                    rights 
                 Shares            Voting                            rights 
                                   Rights 
-------------  ----------------  ----------------  --------------  ------------------------  ------------------------- 
                                                    Direct          Direct     Indirect       Direct        Indirect 
-------------      ------------    ------------    --------------  ---------  -------------  ------------  ----------- 
 GB0031030819   22,950,000        22,950,000        23,950,000      0          23,950,000     0             5.05% 
               ----------------  ----------------  --------------  ---------  -------------  ------------  ----------- 
 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of            Expiration      Exercise/                         Number of voting            % of voting 
 financial           date            Conversion                        rights that                 rights 
 instrument                          Period                            may be 
                                                                       acquired if 
                                                                       the 
                                                                       instrument 
                                                                       is 
                                                                       exercised/ 
                                                                       converted. 
-----------------  --------------  --------------------------------  --------------------------  --------------------- 
 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of          Exercise        Expiration      Exercise/         Number of voting            % of voting 
 financial         price          date            Conversion         rights instrument           rights 
 instrument                       (xvii)          period             refers to 
                                                  (xviii) 
---------------  --------------  --------------  ----------------  --------------------------  ----------------------- 
                                                                                                Nominal       Delta 
---------------  --------------  --------------  ----------------  --------------------------  ------------  --------- 
 
 
 Total (A+B+C) 
---------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                              Percentage of voting rights 
---------------------------------------------------  ----------------------------------------------------------------- 
 23,950,000                                           5.05% 
---------------------------------------------------  ----------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
----------------------------------------------------------------------------- 
 
 
 Proxy Voting: 
----------------------------------------------------------------------------- 
 10. Name of the proxy holder: 
-------------------------------------------------------------  -------------- 
 11. Number of voting rights proxy 
  holder will cease 
  to hold: 
-------------------------------------------------------------  -------------- 
 12. Date on which proxy holder will 
  cease to hold 
  voting rights: 
-------------------------------------------------------------  -------------- 
 
 
  13. Additional information: 
-------------------------------------------------------------  -------------- 
 14. Contact name:                                              Rahul Kunder 
-------------------------------------------------------------  -------------- 
 15. Contact telephone number:                                  020 3824 4506 
-------------------------------------------------------------  -------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLPGUGPQUPMGQP

(END) Dow Jones Newswires

June 22, 2017 12:22 ET (16:22 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Alliance Pharma Charts.